Loading…
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-71M | $-66M | $-49M | -33.8% | -100.0% | 34.7% |
| 2024 | $1M | $-55M | $-49M | $-45M | -39.4% | - | 16.2% |
| 2023 | $0M | $-48M | $-42M | $-41M | -28.6% | - | 8.3% |
| 2022 | $0M | $-40M | $-39M | $-34M | -21.6% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0.85 | 0 |
| Operating Revenue | - | 0 | 0 | 0.85 | 0 |
| Operating Expense | - | 41.66 | 50.36 | 57.48 | 72.84 |
| Research And Development | - | 30 | 38.12 | 42.34 | 55.97 |
| Selling General And Administration | - | 11.66 | 12.24 | 15.13 | 16.87 |
| Total Expenses | - | 41.66 | 50.36 | 57.48 | 72.84 |
| Operating Income | - | -41.66 | -50.36 | -56.62 | -72.84 |
| Total Operating Income As Reported | - | -41.66 | -50.36 | -56.62 | -72.84 |
| EBITDA | - | -39.75 | -48.47 | -54.87 | -71.37 |
| Normalized EBITDA | - | -39.82 | -48.47 | -54.87 | -71.37 |
| EBIT | - | -41.66 | -50.36 | -56.62 | -72.84 |
| Interest Income | - | 2.36 | 7.90 | 7.30 | 6.40 |
| Interest Expense | 0.37 | 0 | - | - | - |
| Net Interest Income | - | 2.36 | 7.90 | 7.30 | 6.40 |
| Other Non Operating Income Expenses | - | - | -0.03 | -0.05 | -0.05 |
| Other Income Expense | - | 0.07 | -0.03 | -0.05 | -0.05 |
| Interest Income Non Operating | - | 2.36 | 7.90 | 7.30 | 6.40 |
| Interest Expense Non Operating | 0.37 | 0 | - | - | - |
| Net Non Operating Interest Income Expense | - | 2.36 | 7.90 | 7.30 | 6.40 |
| Pretax Income | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Tax Provision | 0 | 0 | 0 | 0 | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Net Income From Continuing And Discontinued Operation | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Net Income From Continuing Operation Net Minority Interest | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Net Income | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Net Income Common Stockholders | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Net Income Including Noncontrolling Interests | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Normalized Income | - | -39.30 | -42.49 | -49.38 | -66.49 |
| Diluted NI Availto Com Stockholders | - | -39.22 | -42.49 | -49.38 | -66.49 |
| Basic Average Shares | 62.87 | 105.19 | 127.03 | 137.15 | - |
| Diluted Average Shares | 62.87 | 105.19 | 127.03 | 137.15 | - |
| Reconciled Depreciation | - | 1.90 | 1.89 | 1.75 | 1.47 |
| Total Unusual Items | -50.58 | 0.07 | 0 | - | - |
| Total Unusual Items Excluding Goodwill | -50.58 | 0.07 | 0 | - | - |
| Special Income Charges | -50.58 | 0.07 | 0 | - | - |
| Other Special Charges | 50.62 | - | - | - | - |
| General And Administrative Expense | - | 11.66 | 12.24 | 15.13 | 16.87 |
| Other Gand A | - | 11.66 | 12.24 | 15.13 | 16.87 |
| Gain On Sale Of Ppe | 0.04 | 0.07 | 0 | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Compass Therapeutics, Inc.this co. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Community Health Systems, Inc. | CYH | $393M | 0.77 | -0.28 | -36.5% | 5.53 |
| TruBridge, Inc. | TBRG | $391M | 89.74 | 2.20 | 2.4% | 12.54 |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Benitec Biopharma Inc. | BNTC | $380M |
| - |
| - |
| - |
| - |
| - |
| -10.01 |
| 3.90 |
| -39.0% |
| -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M | 25.26 | 2.67 | 10.6% | 7.36 |
| CapsoVision, Inc. | CV | $377M | -14.88 | 28.41 | -190.9% | -14.73 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Peer Median | - | -3.75 | 1.86 | -37.7% | -3.28 | |